|本期目录/Table of Contents|

[1]张诚实,陈荣荣,秦二云,等.动态测定血浆长链非编码RNA SOX2-OT在COPD相关性肺动脉高压患者中的临床意义[J].中华肺部疾病杂志,2024,(06):895-900.[doi:10.3877/cma.j.issn.1674-6902.2024.06.008
]
　Zhang Chengshi,Chen Rongrong,Qin Eryun,et al.Clinical implications of dynamic determination of plasma long non-coding RNA SOX2-OT in patients with COPD-associated pulmonary hypertension[J].,2024,(06):895-900.[doi:10.3877/cma.j.issn.1674-6902.2024.06.008
]
点击复制

动态测定血浆长链非编码RNA SOX2-OT在COPD相关性肺动脉高压患者中的临床意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年06期
页码:
895-900
栏目:
论著
出版日期:
2024-12-25

文章信息/Info

Title:
Clinical implications of dynamic determination of plasma long non-coding RNA SOX2-OT in patients with COPD-associated pulmonary hypertension
作者:
张诚实; 陈荣荣; 秦二云; 张 青; 刘 明; 冯契靓; 赵云峰
200125 上海,上海市浦东新区浦南医院呼吸内科
Author(s):
Zhang Chengshi;  Chen Rongrong;  Qin Eryun;  Zhang Qing;  Liu Ming;  Feng Qiliang;  Zhao Yunfeng.
Department of Respiratory Disease, Punan Hospital, Pudong New Area, Shanghai 200125, China
关键词:
急性加重期; 肺疾病; 慢性阻塞性;  肺动脉高压;  长链非编码RNA;  SOX2-OT
Keywords:
Acute exacerbation of chronic obstructive pulmonary disease;  Pulmonary hypertension;  Long non-coding RNA;  SOX2-OT;  Prognosis
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2024.06.008
摘要:
目的 分析动态测定血浆长链非编码RNA SOX2-OT在慢性阻塞性肺疾病(chronic obstructive pulmonary, COPD)相关性肺动脉高压(pulmonary hypertension, PH)中的临床意义。方法 选择2020年10月至2023年1月我院收治的120例COPD急性加重期(acute exacerbation COPD, AECOPD)患者为对象,根据肺动脉收缩压(pulmonary arterial systolic pressure, PASP),分为对照组78例(PASP<50 mmHg),观察组42例(PASP≥50 mmHg)。动态测定患者入院时、入院10天、3个月、6个月、12个月的血浆长链非编码RNA SOX2-OT、PASP、白介素-6(interleukin-6, IL-6)、IL-8、氨基末端脑利钠肽前体(N-terminal pro brain natriuretic peptide, NT-ProBNP)、动脉血气、肺功能、6分钟步行距离。记录12个月随访期内急性加重次数和预后。结果 两组比较,入院时、入院10天PASP、血浆长链非编码RNA SOX2-OT、IL-6、IL-8、血浆NT-ProBNP、pH、动脉血氧分压(arterial partial pressure of oxygen, PaO2)、二氧化碳分压(partial pressure of carbon dioxide, PaCO2)、第1秒用力呼气容积占预计值的百分比(percentage of forced expiratory volume in one second, FEV1%)、肺一氧化碳弥散量(diffusing capacity of the lung for carbon monoxide, DLCO)、6分钟步行距离差异有统计学意义(P<0.05)。对照组入院10天与入院时比较,除PASP、血浆长链非编码RNA SOX2-OT外,其余9项指标差异有统计学意义(P<0.05)。观察组入院10天与入院时比较,上述11项指标差异有统计学意义(P<0.05)。对照组3个月、6个月、12个月两两比较,上述11项指标差异无统计学意义(P>0.05)。观察组12个月与3个月、6个月比较,PASP、血浆长链非编码RNA SOX2-OT、NT-ProBNP差异有统计学意义(P<0.05),IL-6、IL-8差异无统计学意义(P>0.05)。观察组3个月、6个月、12个月比较,pH、PaO2、PaCO2、FEV1%、DLCO、6分钟步行距离差异有统计学意义(P<0.05)。观察组12个月随访期间急性加重平均次数(2.93±0.54)次,死亡3例(7.14%)高于对照组(0.91±0.22)次,0例(P<0.05)。结论 AECOPD相关肺动脉高压血浆长链非编码RNA SOX2-OT水平高于不合并肺动脉高压的AECOPD患者; 动态测定血浆长链非编码RNA SOX2-OT水平对于判断COPD急性加重、COPD相关肺动脉高压预后有临床意义。
Abstract:
Objective To investigate clinical implications of dynamic determination of plasma long non-coding RNA SOX2-OT in patients with pulmonary hypertension(PH)associated with chronic obstructive pulmonary disease(COPD). Methods It was selected that 120 patients with acute exacerbation of COPD(AECOPD)as the study subjects in our hospital from October 2020 to January 2023. According to the level of pulmonary artery systolic pressure(PASP), the patients were divided into AECOPD group(control group, n=78)and AECOPD-associated PH group(observation group, n=42). Plasma long non-coding RNA SOX2-OT, interleukin(IL)-6, IL-8, and N-terminal pro brain natriuretic peptide(NT-ProBNP), PASP, arterial blood gas, lung function, and 6-minute walking distance(6MWD)in the two groups were dynamically determined at admission, as well as 10 days, 3 months, 6 months, and 12 months after admission. Number of times of AECOPD and rates of mortality in the two groups were recorded during the 12 months of follow-up period. Results There were statistical differences with respect to 11 variables including the plasma long non-coding RNA SOX2-OT, IL-6, IL-8, and NT-ProBNP, PASP, pH value, PaO2, PaCO2, the percentage of forced expiratory volume in one second(FEV1%), the diffusing capacity for carbon monoxide(DLCO), and 6MWD, between two groups, at admission and 10 days after admission, respectively(all P<0.05). Except for the plasma long non-coding RNA SOX2-OT and PASP, the rest 9 variables 10 days after admission were statistically different from those at admission in the control group(all P<0.05), whereas all the 11 variables above 10 days after admission were statistically different from those at admission in the observation group(all P<0.05). The pairwise comparison among patients at 3-month, 6-month, and 12-month demonstrated no statistical significance for all the 11 parameters above in the control group(all P>0.05). There were statistical differences in the PASP and plasma levels of long non-coding RNA SOX2-OT and NT-ProBNP(all P<0.05), while there were no statistical difference in the plasma levels of IL-6 and IL-8(both P>0.05), when comparing patients at 12-month with those at 3-month and 6-month, respectively, in observation group. There were statistical differences with regard to the pH value, PaO2, PaCO2, FEV1%, DLCO, and 6 MWD, in the pairwise comparisons among patients at 3-month, 6-month, and 12-month in the observation group(all P<0.05). The mean number of times of AECOPD and mortality rate in the observation group were statistically greater than those in the control group, respectively, during the 12 months of followup period(both P<0.05). Conclusion Plasma level of long non-coding RNA SOX2-OT in AECOPD patients with AECOPD-associated PH is significantly higher than that in those without. Dynamic determination of plasma level of long non-coding RNA SOX2-OT has certain clinical implications in the prediction of AECOPD and prognosis of patients with COPD-associated PH.

参考文献/References:

1 Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
2 Chaouat A, Naeije R, WeitzenbIum E. Pulmonary hypertension in COPD[J]. Eur Respir J, 2008, 32(5): 1371-1385.
3 Marc Humbert, Gabor Kovacs, Marius M Hoeper, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38): 3618-3731.
4 任成山, 卞士柱, 胡明冬. 肺动脉高压的成因及治疗新理念[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(1): 1-5.
5 Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology(ESC)and the european respiratory society(ERS), endorsed by the international society of heart and lung transplantation(ISHLT)[J]. Eur Heart J, 2009, 30(20): 2493-2537.
6 Gu S, Li G, Zhang X, et al. Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension[J]. Mol Med Rep, 2015, 11(4): 2631-2643.
7 Wang X, Yan C, Xu X, et al. Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model[J]. Gene, 2016, 579(1): 23-28.
8 Amaral PP, Neyt C, Wilkins SJ, et al. Complex architecture and regulated expression of the Sox2ot locus during vertebrate development [J]. RNA, 2009, 15(11): 2013-2027.
9 Jiang Y, Hei B, Hao W, et al. Clinical value of lncRNA SOX2-OT in pulmonary arterial hypertension and its role in pulmonary artery smooth muscle cell proliferation, migration, apoptosis, and inflammatory[J]. Heart Lung, 2022, 55: 16-23.
10 Wang Y, Wu NY, Luo X, et al. SOX2OT, a novel tumor-related long non-coding RNA[J]. Biomed Pharmacother, 2020: 109725.
11 臧九高, 王梅香, 沙 翔. 慢性心力衰竭患者外周血lncRNA SOX2-OT和miR-2355-3p表达水平及意义[J]. 中南医学科学杂志, 2023, 51(3): 437-440.
12 Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD[J]. Eur Respir J, 2004, 23(1): 28-33.
13 Thompson A, Lawrie A. Targeting vascular remodeling to treat pulmonary arterial hypertension[J]. Trends Mol Med, 2017, 23(1): 31-45.
14 Leopold JA, Maron BA. Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension[J]. Int J Mol Sci, 2016, 17(5): 761.
15 Gu S, Li G, Zhang X, et al. Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension[J]. Mol Med Rep, 2015, 11(4): 2631-2643.
16 Wang X, Yan C, Xu X, et al. Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model[J]. Gene, 2016, 579(1): 23-28.
17 Fantes J, Ragge NK, Lynch SA, et al. Mutations in SOX2 cause anophthalmia [J]. Nat Genet, 2003, 33(4): 461-463.
18 Askarian-Amiri ME, Seyfoddin V, Smart CE, et al. Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer[J]. PLoS One, 2014, 9: e102140.
19 Hou Z, Zhao W, Zhou J, et al. A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival[J]. Int J Biochem Cell B, 2014, 53: 380-388.
20 Shahryari A, Rafiee MR, Fouani Y, et al. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coup regulated with SOX2 and OCT4 in esophageal squamous cell carcinoma [J]. Stem Cells, 2014, 32(1): 126-134.
21 Dong H, Zeng L, Wu Y, et al. SOX2-OT/SOX2 axis regulates lung cancer H520 cell migration via Gli1-mediated epithelial-mesenchymal transition[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2022, 42(10): 1431-1439.
22 Li PY, Wang P, Gao SG, et al. Long noncoding RNA SOX2-OT: Regulations, functions, and roles on mental illnesses, cancers, and diabetic complications[J]. Biomed Res Int, 2020, 2020: 2901589.
23 Tao J, Hu Y. Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis[J]. BMC Cardiovasc Disord, 2022, 22(1): 211.
24 Wang H, Hu Q, Tong Y, et al. LncRNA SOX2-OT regulates miR-192-5p/RAB2A axis and ERK pathway to promote glioblastoma cell growth[J]. Cell Cycle, 2021, 20(19): 2010-2020.
25 Yang G, Lin C. Long Noncoding RNA SOX2-OT exacerbates hypoxia-induced cardiomyocytes injury by regulating miR-27a-3p/TGFβR1 axis[J]. Cardiovasc Ther, 2020: 2016259.
26 Guo Y, Liu Y, Wang H, et al. Long noncoding RNA SRY-box transcription factor 2 overlapping transcript participates in Parkinson's disease by regulating the microRNA-942-5p/nuclear apoptosis-inducing factor 1 axis[J]. Bioengineere, 2021, 12(1): 8570-8582.
27 Woowiec , Mdlewska M, Osiak J, et al. MicroRNA and incRNA as the future of pulmonary arterial hypertension treatment[J]. Int J Mol Sci, 2023, 24(11): 9735.
28 Yi C, Gu T, Li Y, et al. Depression of long non-coding RNA SOX2 overlapping transcript attenuates lipopolysaccharide-induced injury in bronchial epithelial cells via miR-455-3p/phosphatase and tensin homolog axis and phosphatidylinositol 3-kinase/protein kinase B pathway[J]. Bioengineered, 2022, 13(5): 13643-13653.
29 He M, Shen J, Zhang C, et al. Long-chain non-coding RNA metastasis-related lung adenocarcinoma transcript 1(MALAT1)promotes the proliferation and migration of human pulmonary artery smooth muscle cells(hPASMCs)by regulating the microRNA-503(miR-503)/toll-like receptor 4(TLR4)signal axis[J]. Med Sci Monit, 2020, 26: e923123.
30 Hui Huang, Limei Yang. Research progress of inflammatory factors in chronic obstructive pulmonary disease with pulmonary hypertension at high altitude[J]. Altern Ther Health Med, 2023, 29(8): 689-693.
31 张诚实, 赵云峰, 鲁晓怡, 等. 血浆鸢尾素在稳定期慢性阻塞性肺病相关肺动脉高压中的临床价值[J]. 老年医学与保健, 2022, 28(1): 140-143.
32 Stubbs HD, Cannon J, Knightbridge E, et al. Sendaway capillary NT-proBNP in pulmonary hypertension[J]. BMJ Open Respir Res, 2024, 11(1): e002124.

备注/Memo

备注/Memo:
基金项目: 上海市浦东新区卫生系统重点学科建设资助项目(PWZxk2022-24)
上海市浦东新区卫生系统临床特色学科建设资助(PWYts2021-04)
通信作者: 赵云峰, Email: yfzh71@126.com
更新日期/Last Update: 2024-12-25